Northwest Biotherapeutics | NWBO - Cash And Equivalent


Northwest Biotherapeutics reported $4.56M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 3.46M 6.08M Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Celldex Therapeutics USD 28.87M 7.17M Dec/2025
Eisai JPY 301.65B 16.27B Sep/2025
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
Merck USD 18.17B 10.16B Sep/2025
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Plus Therapeutics USD 8.55M 2.45M Dec/2023
Roche Holding CHF 7.55B 579M Jun/2025